BAXTER
ActiveSummary
BAXTER has been active since 1968 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €83.8m and a net result of €6.2m. Equity has been growing by about 10% per year since 2018. Its solvency ranks better than 57% of 94 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
Source: KBO- Status
- Active Normal situation
- Registered office
- 11 active companies are registered at this address Source: KBO register, as of 2 November 2026.
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21201
- Joint committees
- 116 Paritair Comité voor de scheikundige nijverheid
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 2025
- Establishment units
- 2.105.442.804 7860 Lessines, since 01-06-1970
- 2.215.045.973 7860 Lessines, since 21-12-2012
- Financial year end
- 31 December
- Peppol
- Reachable since 30-01-2026
Board and ownership
Board
- Annelies BryonManaging director
- Frédéric YannartDirector · since 01-01-2021
- Guy In 't VenDirector · since 15-07-2023
- Auditor
- PwC Réviseurs d'Entreprises SRL
Shareholders
- Baxter International INCconsolidatesannual accounts 2025
- Holdings
- Shares in 4 companies including Baxter Medico Farmaceutica Lda and BAXTER BELGIUM
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
Annual accounts 2025
- Turnover
- €106.6m
- ▲ 2.2%
- Profit
- €6.2m
- ▼ 64.0%
- Equity
- €83.8m
- ▲ 7.6%
- Total assets
- €160.0m
- ▲ 3.4%
- Employees on 31-12-2025
- 967
- ▼ 1.9%
Standalone figures, without subsidiaries
Score breakdownraises riskLiquidity: current ratio 1.44lowers riskSize: turnover €106.6m, 901.3 FTE, total assets €160.0m, files consolidated accountsFounded in 1968Equity €83.8m (52.4% of total assets)Show the evidence
Checked score
Score 2025
91
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 63% of companies in pharmaceuticals (NACE 21)
Financial strength · tick: 2024
Strong
Solvency
77+2
equity 52.4% of total assets
Liquidity
64-24
short-term debt 38.7%
Profitability
75-7
return on assets 3.8%
Bankruptcy probability within 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.2%▲ +0.1 percentage points vs 06-2025highest value
08-2025: 0.1%▼ -0.1 percentage points vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026lowest value
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.2%▲ +0.1 percentage points vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.2%● unchanged vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Credit of up to €7,600,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.44 (2.84 in 2024), below the usual 1.5. Short-term debt is 38.7% of total assets. 47.6% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21). It does better than 59% of them on solvency, 93% on liquidity, 59% on profitability and 42% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-07-2026, 23 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
23 days early
2024
22 days early
2023
22 days early
2022
21 days early
2021
19 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 21 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 10 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
- Positive: 2nd largest company by total assets in Hainaut, Pharmaceuticals sectorin the Checked rankings No. 2 View
- Result fell in 2025the 2024 profit included a one-off income of €10.4m ▼ 64.0% View
- Positive: 8 profitable years in a rowprofit 2025: €6.2m 8 years View
- Positive: Always filed on timeaccounts within the deadline every year 5 years View
Recent changes
- · Gazette deed Appointment: SRL PwC Reviseurs d'Entreprises (statutory auditor)Permanent representative: Romain Seffer
- · Gazette deed Resignation: Lionel Rosoux (director and managing director)Appointment: Abdellah El Kacem (director)
- · Gazette deed Resignation: Herman Jacobs (director)
Companies linked to BAXTER
Comparable companies
These companies have the same main activity as BAXTER: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €63m and €377m, founded between 1941 and 1999.
| Company | Total assets | Turnover |
|---|---|---|
| BAXTER Lessines | €160.0m | €106.6m |
| Novartis Manufacturing Puurs-Sint-Amands | €285.2m | €256.5m |
| Organon Heist Heist-op-den-Berg | €349.6m | €287.4m |
| KELA - Kempisch Laboratorium - Kela Laboratoria Hoogstraten | €63.2m | €55.2m |
| Novo Nordisk Production Belgium SA Brussel | €153.5m | €258.6m |
| PHYSIOL Liège | €245.1m | €66.4m |
| Pfizer Elsene | €377.4m | €358.3m |
Key facts about BAXTER
- What is the company number of BAXTER?
- The company number of BAXTER is 0403.093.693. The VAT number is the same number with BE in front: BE 0403.093.693.
- Where is BAXTER based?
- The registered office is at Boulevard René Branquart(L) 80, 7860 Lessines.Company details
- What does BAXTER do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
- What is the legal form of BAXTER?
- The legal form of BAXTER is Public limited company (NV).
- When was BAXTER founded?
- BAXTER was founded on 01-01-1968.
- Is BAXTER still active?
- Yes, BAXTER is an active enterprise in the KBO register.
- How many employees does BAXTER have?
- BAXTER had an average of 901.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does BAXTER fall under?
- In its 2025 annual accounts, BAXTER states joint committees 116 (Paritair Comité voor de scheikundige nijverheid) and 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid).
- What is the turnover of BAXTER?
- The turnover of BAXTER was €106.6m in financial year 2025, according to the filed annual accounts.
- Is BAXTER profitable?
- In financial year 2025, BAXTER made a profit of €6.2m.
- Where can I find the annual accounts of BAXTER?
- BAXTER filed 72 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of BAXTER due?
- BAXTER must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.